<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04857502</url>
  </required_header>
  <id_info>
    <org_study_id>20-002256</org_study_id>
    <secondary_id>NCI-2021-01793</secondary_id>
    <secondary_id>20-002256</secondary_id>
    <nct_id>NCT04857502</nct_id>
  </id_info>
  <brief_title>99mTc-PSMA-I&amp;S Biodistribution in Patients With Prostate Cancer</brief_title>
  <official_title>99mTc-PSMA-I&amp;Amp;S in Patients With Prostate Cancer: An Exploratory Biodistribution Study With Histopathology Validation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This exploratory study conducted under the RDRC program studies the biodistribution of&#xD;
      99mTc-PSMA-I&amp;S in patients with prostate cancer who undergo pelvic lymph node dissection.&#xD;
      Prostate specific membrane antigen (PSMA)-targeted radio-guided surgery uses the preoperative&#xD;
      intravenous administration of a PSMA-ligand called PSMA-imaging and surgery (I&amp;S) labeled&#xD;
      with the gamma-emitter radioisotope Technetium-99m (99mTc). Giving 99mTc-PSMA-I&amp;S may detect&#xD;
      PSMA-expressing lymph nodes during surgery using a gamma probe and may help guide doctors to&#xD;
      detect prostate cancer that has spread to the lymph nodes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To define the biodistribution of 99mTc-based PSMA imaging and surgery agent&#xD;
      (99mTc-PSMA-I&amp;S) in normal and malignant tissues of patients with prostate cancer (PCa) with&#xD;
      histopathology validation, when available.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To correlate the 99mTc-PSMA-I&amp;S accumulation within tumor lesions observed by in-vivo&#xD;
      single-photon emission computed tomography (SPECT), ex-vivo gamma measurements and level of&#xD;
      prostate-specific membrane antigen (PSMA) expression quantified by histopathology, when&#xD;
      available.&#xD;
&#xD;
      II. To define the best time-point for radio-guided surgery (RGS) with the highest&#xD;
      tumor-to-background ratio following 99mTc-PSMA-I&amp;S administration.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      The first 5 patients receive an initial dose of 99mTc-PSMA-I&amp;S intravenously (IV) followed by&#xD;
      5 SPECT/CT scans at 3-5, 5-20, 17-21, 25-29, and 40-46 hours later. These 5 patients then&#xD;
      receive a second dose of 99mTc-PSMA-I&amp;S IV and then undergo standard of care surgery. All&#xD;
      subsequent patients receive one dose of 99mTc-PSMA-I&amp;S IV before surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The biodistribution of 99mTc-PSMA-I&amp;S in normal and malignant tissues of patients with prostate cancer will be measured by average and maximum standardized uptake value (SUVmean and SUVmax)</measure>
    <time_frame>time from injection to imaging (range: 1-46 hours)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>99mTc-PSMA-I&amp;S accumulation within tumor lesions observed by in-vivo SPECT (SUVmean and SUVmax) will be correlated with ex-vivo gamma measurements (counts/minute) and level of PSMA expression quantified by histopathology (IHC score)</measure>
    <time_frame>time from injection to imaging (range: 1-46 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The best time-point for 99mTc-PSMA-I&amp;S radioguided surgery will be determined by the tumor-to-background uptake ratio (TBR) using the time-activity curve function</measure>
    <time_frame>time from injection to imaging (range: 1-46 hours)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostate Carcinoma</condition>
  <condition>Recurrent Prostate Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (99mTc-PSMA-I&amp;S, SPECT/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first 5 patients receive an initial dose of undergo 99mTc-PSMA-I&amp;S IV followed by 5 SPECT/CT scans at 3-5, 5-20, 17-21, 25-29, and 40-46 hours later. These 5 patients then receive a second dose of 99mTc-PSMA-I&amp;S IV and then undergo standard of care surgery. All subsequent patients receive one dose of 99mTc-PSMA-I&amp;S IV before standard of care surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>99mTc-based PSMA Imaging and Surgery Agent</intervention_name>
    <description>Given via IV injection</description>
    <arm_group_label>Diagnostic (99mTc-PSMA-I&amp;S, SPECT/CT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo SPECT/CT</description>
    <arm_group_label>Diagnostic (99mTc-PSMA-I&amp;S, SPECT/CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT Scan</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single Photon Emission Computed Tomography</intervention_name>
    <description>Undergo SPECT/CT</description>
    <arm_group_label>Diagnostic (99mTc-PSMA-I&amp;S, SPECT/CT)</arm_group_label>
    <other_name>Medical Imaging, Single Photon Emission Computed Tomography</other_name>
    <other_name>Single Photon Emission Tomography</other_name>
    <other_name>single-photon emission computed tomography</other_name>
    <other_name>SPECT</other_name>
    <other_name>SPECT imaging</other_name>
    <other_name>SPECT SCAN</other_name>
    <other_name>SPET</other_name>
    <other_name>tomography, emission computed, single photon</other_name>
    <other_name>Tomography, Emission-Computed, Single-Photon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men with PCa (primary or recurrent disease)&#xD;
&#xD;
          -  Men who received a 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography&#xD;
             (CT) for staging or restaging&#xD;
&#xD;
          -  Men with evidence of lymph nodes (LNs)-positive disease on 68Ga-PSMA-11 PET/CT&#xD;
&#xD;
          -  Men who are scheduled for pelvic LN dissection (PLND)&#xD;
&#xD;
          -  Men who can provide oral and written informed consent&#xD;
&#xD;
          -  Men who can comply with study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who started any PCa treatment between study enrollment and surgery&#xD;
&#xD;
          -  Technically inaccessible nodal location&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremie Calais, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ankush Sachdeva</last_name>
    <phone>310-794-3421</phone>
    <email>ASachdeva@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathleen Nguyen</last_name>
    <phone>310 206-7372</phone>
    <email>KathleenNguyen@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ankush Sachdeva</last_name>
      <phone>310-794-3421</phone>
      <email>ASachdeva@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen Nguyen</last_name>
      <phone>310 206-7372</phone>
      <email>KathleenNguyen@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeremie Calais, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

